Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
1
17%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Not yet recruiting2
Recruiting2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

active_not_recruiting117%
completed117%
not_yet_recruiting233%
recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
not_yet_recruitingphase_3

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

NCT07554846
not_yet_recruitingphase_2

Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

NCT07050524
recruiting

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

NCT06926179
active_not_recruitingnot_applicable

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

NCT06762158
recruiting

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

NCT06317558
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07554846Phase 3

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

Not Yet Recruiting
NCT07050524Phase 2

Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

Not Yet Recruiting
NCT06926179

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Recruiting
NCT06762158Not Applicable

NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC

Active Not Recruiting
NCT06317558

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Recruiting
NCT05273827

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6